与患者谈论阿斯利康疫苗资源
卫生部为卫生专业人员创建了一个资源，以协助与患者讨论阿斯利康 COVID-19 疫苗。
该资源详细介绍了阿斯利康疫苗的关键事实，包括当前建议、有效性以及有关血小板减少症 (TTS) 血栓形成风险的信息。
您可以通过以下链接访问资源：
更新的免疫参考页：TTS、G6PD 和 COVID-19 疫苗和过敏
我们最近更新了一些免疫参考页面，以包含有关 COVID-19 疫苗的最新信息和建议。要查看这些页面，请点击以下链接：
微血管内皮细胞： 血栓形成伴血小板减少综合征 (TTS)
微血管内皮细胞： G6PD 缺乏症和疫苗
微血管内皮细胞： COVID-19 疫苗和过敏
BBC：新冠疫苗：不，你的疫苗没有磁性
人们将磁铁贴在声称接种了新冠疫苗的地方的视频在 TikTok 和 Instagram 等社交媒体平台上获得了数百万次观看。
有些人说疫苗中一定有磁性的东西，而另一些人则更进一步说这是微芯片的证据——这种理论并不正确。
BBC Reality Check 的杰克·古德曼揭穿了所谓的 #magnetchallenge。
要了解更多信息，请点击以下链接：
新的免疫参考页面：COVID-19 疫苗接种：劳动力培训和应用流程
由于推出 COVID-19 疫苗需要进行大量免疫接种，因此需要扩大当前的免疫接种队伍。需要专门的培训和教育，以确保免疫接种人员得到适当的培训，以便安全有效地接种每种疫苗。
我们的新参考页面“COVID-19 疫苗接种：劳动力培训和申请流程”详细介绍了有关维多利亚州 COVID-19 免疫接种劳动力每位成员培训要求的常见问题。
要了解更多信息，请点击以下链接：
Raising Children Network - new COVID-19 vaccination: pregnancy and breastfeeding resource
MVEC 与 育儿网 to develop a new resource focused on providing COVID-19 vaccine recommendations for women who are pregnant, breastfeeding or planning pregnancy.
To view this article follow the link below:
COVID-19 vaccination: pregnancy and breastfeeding
Further information on vaccines for pregnant and breastfeeding women can be found via our immunisation reference pages below:
BBC News: Covid: Pfizer and AstraZeneca jabs work against Indian variant - study
A study conducted by Public Health England (PHE) has shown that either of the Pfizer or AstraZeneca COVID-19 vaccine brands are highly effective against the COVID-19 Indian strain. Two weeks after the administration of dose 2, the Pfizer vaccine was found to be 88% effective at stopping symptomatic disease and the AstraZeneca vaccine was 60% effective.
The effectiveness of only 1 dose of either brand was reduced to 33%, highlighting the importance of administering both doses.
要了解更多信息，请点击以下链接：
BBC News: Covid: Pfizer and AstraZeneca jabs work against Indian variant - study
nature: COVID vaccines and kids- five questions as trials begin
With a number of COVID-19 vaccine trials now focusing on paediatric populations across various age groups, specific factors need to be considered.
The following article explores issues such as the consent process for paediatric involvment, the robust immune responses of children, and monitoring for signs of exacerbated immune responses and multisystem inflammatory syndrome in children.
Whilst severe COVID-19 disease in children is rare, the immunisation of children against COVID-19 disease will play an important role in achieving herd immunity.
To read more, please read the article below:
nature: COVID vaccines and kids: five questions as trials begin
New resource: Australia's COVID-19 vaccine rollout
For easily accessible information relating to the COVID-19 vaccine rollout, the Australian Government Department of Health have created a new resource page. This page will be updated daily and describes the number of vaccine doses administered via the various providers, makes comparisons to international COVID-19 vaccine programs, and provides other sources of useful data.
To view this page please refer to the link below:
Australian Government Department of Health: Australia's COVID-19 vaccine rollout
A recording of the 26th April CVU mini is now available
Thank you to all who attended our recent CVU miniseries event COVID-19 疫苗：维多利亚州的报告和管理 on 26th April 2021.
This interactive webinar looked at the latest vaccine safety questions around COVID-19 vaccines, guidelines for referring patients for evaluation prior to vaccination (VicSIS), and reporting safety events related to COVID-19 vaccines.
A recording of this event is now available via our education portal.
To access this recording please follow the link below:
VACSIG Webinar Events: Register to attend
The Vaccination Special Interest Group (VACSIG) will be hosting a webinar on Wednesday 5 May featuring a panel of expert speakers including MVEC's Professor Jim Buttery and A/Prof Nigel Crawford. The topic for the webinar is COVID-19 vaccines and rare side effects - now blood clots/bleeding, what’s next?. This event is open to both ASID members and non-members. Further information and details on registration can be found via the link below:
VACSIG Webinar Wednesday 5 May